Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis
Authors' conclusion
Anti-Sp4 and anti-CCAR1 autoantibodies are less common in the adult UK anti-TIF1γ-positive myositis population compared with published data from the USA, limiting their use as biomarkers for cancer risk. In patients with juvenile onset disease, anti-Sp4 is less frequent in UK patients compared with the USA, but the prevalence of anti-CCAR1 autoantibodies is similar.
Study context
- Population
- UK patients with adult-onset and juvenile-onset anti-TIF1γ-positive myositis
- Participants
- 51 / 55 / 24
- Exposure
- UK adult-onset idiopathic inflammatory myopathy (IIM) vs UK JDM, all anti-TIF1γ positive; healthy controls
- Adult-onset IIMn = 51
- JDMn = 55
- Healthy controlsn = 24reference
- Outcome
- Frequency of anti-Sp4 and anti-CCAR1 autoantibodies
Methodological detailsELISA screening
- ELISA screening
Main finding
As reported in the abstract
UK adult anti-TIF1γ+ IIM: anti-Sp4
4%
2/51
UK adult anti-TIF1γ+ IIM: anti-CCAR1
16%
8/51
UK juveniles: anti-CCAR1
13%
7/55
Observational data: associations, not effects.
Further findings
Cancer in UK adult anti-TIF1γ+ myositis
- Adults with cancer
- Nineteen (37%)
- Anti-CCAR1-positive adults with cancer
- 25% (2/8)
- Neither of the two anti-Sp4-positive adults had cancer
Clinical associations of anti-Sp4 and anti-CCAR1
- No anti-Sp4 or anti-CCAR1 clinical associations identified
Original publication
Anti-Sp4 and anti-CCAR1 autoantibodies in UK vs US patients with adult and juvenile-onset anti-TIF1γ-positive myositis. Rheumatology (Oxford). Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →